• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Biogen Idec (NQ:BIIB)

188.02 -2.71 (-1.42%)
Streaming Delayed Price Updated: 4:00 PM EST, Feb 26, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 988,023
Open 190.30
Bid (Size) 185.00 (100)
Ask (Size) 190.25 (300)
Prev. Close 190.73
Today's Range 185.90 - 190.74
52wk Range 110.03 - 202.41
Shares Outstanding 146,800,000
Dividend Yield N/A
Chart for  (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
3 Value Stocks Walking a Fine Line
February 18, 2026
The low valuation multiples for value stocks provide a margin of safety that growth stocks rarely offer. However, the challenge lies in determining whether these cheap assets are genuinely undervalued... 
Via StockStory
News headline image
The 5 Most Interesting Analyst Questions From Biogen’s Q4 Earnings Call
February 13, 2026
Biogen’s fourth-quarter results were received positively by the market, as the company exceeded Wall Street’s revenue and non-GAAP profit expectations despite a year-over-year decline in sales.... 
Via StockStory
Topics Earnings

Performance

YTD
+5.7%
+5.7%
1 Month
+8.6%
+8.6%
3 Month
+3.3%
+3.3%
6 Month
+37.9%
+37.9%
1 Year
+31.1%
+31.1%

More News

Read More
News headline image
1 Unpopular Stock That Deserves a Second Chance and 2 We Find Risky
February 12, 2026
Via StockStory
Biogen Stock To Pop Again? China Fast-Tracks At-Home Alzheimer’s Drug Leqembi ↗
February 08, 2026
Via Stocktwits
News headline image
Biogen Announces Board Chair Transition
February 11, 2026
From Biogen Inc.
Via GlobeNewswire
News headline image
BIIB Q4 Deep Dive: Pipeline Advances and New Product Launches Offset Legacy Headwinds
February 07, 2026
Via StockStory
News headline image
Why Biogen Stock Surged Almost 9% Higher on Friday ↗
February 06, 2026
Via The Motley Fool
What's going on in today's session: S&P500 movers ↗
February 06, 2026
Via Chartmill
News headline image
Biogen (BIIB) Q4 Earnings Preview: The "New Biogen" Emerges as Alzheimer's and Rare Disease Pipelines Take Center Stage
February 06, 2026
Via MarketMinute
Topics Intellectual Property
News headline image
Biogen (BIIB) Q4 2025 Earnings Call Transcript ↗
February 06, 2026
Via The Motley Fool
Topics Earnings
News headline image
Biogen (BIIB) Deep Dive: Navigating the Pivot from MS Giant to Neuro-Innovation Powerhouse
February 06, 2026
Via Finterra
Topics Earnings Economy Intellectual Property
News headline image
Biogen’s (NASDAQ:BIIB) Q4 CY2025: Strong Sales
February 06, 2026
Via StockStory
Topics Artificial Intelligence
News headline image
Biogen (BIIB) Reports Q4: Everything You Need To Know Ahead Of Earnings
February 04, 2026
Via StockStory
Topics Artificial Intelligence World Trade
Stay updated with the S&P500 stocks that are on the move in today's pre-market session. ↗
February 04, 2026
Via Chartmill
News headline image
Nature Medicine Publishes Results from the Pivotal DEVOTE Study of High-Dose Regimen of Nusinersen in Spinal Muscular Atrophy
February 04, 2026
From Biogen Inc.
Via GlobeNewswire
News headline image
1 Cash-Producing Stock to Keep an Eye On and 2 We Find Risky
February 02, 2026
Via StockStory
News headline image
Biogen’s Litifilimab Receives FDA Breakthrough Therapy Designation for Cutaneous Lupus Erythematosus, a Disease With No Targeted Treatment Options
January 28, 2026
From Biogen Inc.
Via GlobeNewswire
News headline image
3 Biotech Stocks That Look Like “Sure-Fire” Winners in 2026 ↗
January 20, 2026
Via MarketBeat
Which S&P500 stocks are gapping on Wednesday? ↗
January 14, 2026
Via Chartmill
News headline image
Biogen Receives European Commission Approval for High Dose Regimen of SPINRAZA® (nusinersen) for Spinal Muscular Atrophy
January 12, 2026
From Biogen Inc.
Via GlobeNewswire
News headline image
3 Reasons to Sell BIIB and 1 Stock to Buy Instead
January 11, 2026
Via StockStory
News headline image
The Trillion-Dollar Pharmacist: A 2026 Deep Dive into Eli Lilly (LLY)
January 09, 2026
Via PredictStreet
Topics Earnings Economy Intellectual Property
News headline image
The Great Decoupling: How the AI Monetization Era Reshaped the Nasdaq in 2025
December 26, 2025
Via MarketMinute
Topics Artificial Intelligence Economy Stocks
News headline image
Biogen Inc. (NASDAQ:BIIB) Shows Strong Technical Setup for Potential Breakout ↗
December 26, 2025
Via Chartmill
News headline image
The Trillion-Dollar Pharma: A Deep Dive into Eli Lilly’s (LLY) Dominance in the Weight-Loss Era
December 25, 2025
Via PredictStreet
Topics Economy Government Intellectual Property

Frequently Asked Questions

Is Biogen Idec publicly traded?
Yes, Biogen Idec is publicly traded.
What exchange does Biogen Idec trade on?
Biogen Idec trades on the Nasdaq Stock Market
What is the ticker symbol for Biogen Idec?
The ticker symbol for Biogen Idec is BIIB on the Nasdaq Stock Market
What is the current price of Biogen Idec?
The current price of Biogen Idec is 188.02
When was Biogen Idec last traded?
The last trade of Biogen Idec was at 02/26/26 04:00 PM ET
What is the market capitalization of Biogen Idec?
The market capitalization of Biogen Idec is 27.60B
How many shares of Biogen Idec are outstanding?
Biogen Idec has 28B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap